List of Abilify Mycite Kit drug patents
Abilify Mycite Kit is owned by Otsuka.
Abilify Mycite Kit contains Aripiprazole.
Abilify Mycite Kit has a total of 34 drug patents out of which 5 drug patents have expired.
Expired drug patents of Abilify Mycite Kit are:
- US9089567
- US7053092
- US8642760
- US9359302
- US8580796
Abilify Mycite Kit was authorised for market use on 13 November, 2017.
Abilify Mycite Kit is available in tablet;oral dosage forms.
Abilify Mycite Kit can be used as acute treatment of manic and mixed episodes associated with bipolar i disorder; adjunctive treatment of major depressive disorder (mdd); treatment of schizophrenia, adjunctive treatment of major depressive disorder (mdd), method of using a receiver to receive a signal from a tablet embedded with a sensor that communicates information through the body of a patient, method of using a logic circuit to stabilize battery voltage supplied to a sensor embedded with a tablet and that communicates information via a signal through the body of a patient to a receiver, method of using a receiver to identify a signal from a tablet embedded with a sensor that communicates information through the body of a patient, acute treatment of manic and mixed episodes associated with bipolar i disorder, treatment of schizophrenia, method of using a tablet embedded with a sensor that communicates information via a signal through the body of a patient to a receiver.
The generics of Abilify Mycite Kit are possible to be released after 15 October, 2033.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8642760 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(6 months ago) | |
| US9359302 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(6 months ago) | |
| US8580796 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(6 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9089567 | OTSUKA | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(1 year, 1 month ago) | |
| US7053092 | OTSUKA | 5-HT1a receptor subtype agonist |
Jan, 2022
(1 year, 1 month ago) | |
| US9387182 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Dec, 2023
(8 months from now) | |
| US8017615 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2024
(1 year, 2 months from now) | |
| US11476952 | OTSUKA | Pharma-informatics system |
Apr, 2026
(3 years from now) | |
| US9125939 | OTSUKA | Carbostyril derivatives and mood stabilizers for treating mood disorders |
Jul, 2026
(3 years from now) | |
| US7978064 | OTSUKA | Communication system with partial power source |
Sep, 2026
(3 years from now) | |
| US8759350 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Mar, 2027
(3 years from now) | |
| US9444503 | OTSUKA | Active signal processing personal health signal receivers |
Nov, 2027
(4 years from now) | |
| US9119554 | OTSUKA | Pharma-informatics system |
Dec, 2028
(5 years from now) | |
| US9060708 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Mar, 2029
(5 years from now) | |
| US9258035 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Mar, 2029
(5 years from now) | |
| US8674825 | OTSUKA | Pharma-informatics system |
Apr, 2029
(6 years from now) | |
| US8956288 | OTSUKA | In-body power source having high surface area electrode |
Jul, 2029
(6 years from now) | |
| US10441194 | OTSUKA | Ingestible event marker systems |
Jul, 2029
(6 years from now) | |
| US8945005 | OTSUKA | Controlled activation ingestible identifier |
Aug, 2029
(6 years from now) | |
| US9433371 | OTSUKA | In-body device with virtual dipole signal amplification |
Sep, 2029
(6 years from now) | |
| US8718193 | OTSUKA | Active signal processing personal health signal receivers |
Dec, 2029
(6 years from now) | |
| US9149577 | OTSUKA | Body-associated receiver and method |
Dec, 2029
(6 years from now) | |
| US8847766 | OTSUKA | Pharma-informatics system |
Mar, 2030
(7 years from now) | |
| US8545402 | OTSUKA | Highly reliable ingestible event markers and methods for using the same |
Apr, 2030
(7 years from now) | |
| US8114021 | OTSUKA | Body-associated receiver and method |
Jun, 2030
(7 years from now) | |
| US11464423 | OTSUKA | In-body power source having high surface area electrode |
Sep, 2030
(7 years from now) | |
| US9941931 | OTSUKA | System for supply chain management |
Nov, 2030
(7 years from now) | |
| US8961412 | OTSUKA | In-body device with virtual dipole signal amplification |
Nov, 2030
(7 years from now) | |
| US8258962 | OTSUKA | Multi-mode communication ingestible event markers and systems, and methods of using the same |
Nov, 2030
(7 years from now) | |
| US8547248 | OTSUKA | Implantable zero-wire communications system |
Dec, 2030
(7 years from now) | |
| US11229378 | OTSUKA | Communication system with enhanced partial power source and method of manufacturing same |
Jul, 2031
(8 years from now) | |
| US9320455 | OTSUKA | Highly reliable ingestible event markers and methods for using the same |
Dec, 2031
(8 years from now) | |
| US10517507 | OTSUKA | Communication system with enhanced partial power source and method of manufacturing same |
Jun, 2032
(9 years from now) | |
| US9268909 | OTSUKA | Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device |
Oct, 2033
(10 years from now) | |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: Treatment of schizophrenia; Adjunctive treatment of major depressive disorder (mdd); Acute treatment of manic and mixed episodes associated with bipolar i disorder; Method of using a receiver to ident...
Dosage: TABLET;ORAL
ABILIFY MYCITE KIT family patents
219
United States
61
Japan
58
China
46
European Union
34
Canada
32
Israel
30
Hong Kong
26
Korea, Republic of
26
Taiwan, Province of China
18
Denmark
18
Australia
17
Spain
14
Singapore
14
Brazil
14
Malaysia
13
Ukraine
12
Mexico
12
Portugal
11
South Africa
11
Russia
11
Poland
10
Norway
8
Cyprus
7
Slovenia
7
Argentina
6
Austria
6
Germany
5
New Zealand
4
Peru
4
Ecuador
4
India
4
Georgia
3
Chile
2
Lithuania
2
Hungary
2
Philippines
1
Finland
1
Morocco
1
Costa Rica
1
Colombia
1
EA
1
Tunisia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic